William N. William

Beneficiencia Portuguesa De São Paulo/Hospital São José
São Paulo, BR 
Beneficiencia Portuguesa De São Paulo/Hospital São José
São Paulo, BR 

Overview

William William practices practicing medicine in São Paulo, Brazil.

His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), and Lung Cancer.

He is actively involved in clinical research, participating in 12 clinical trials.

Gender

Male

Locations

Beneficiencia Portuguesa de São Paulo/Hospital São José
São Paulo, Brazil
Other Locations
University of Texas MD Anderson Cancer Center
Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Single-arm, Multi-institutional, Phase 2 Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers
A Single-arm, Multi-institutional, Phase 2 Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers
Enrollment Status: Completed
Publish Date: August 27, 2026
Intervention Type: Radiation, Drug
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 2
A Phase II Study of OSI-774 in Combination With Cisplatin and Docetaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer
A Phase II Study of OSI-774 in Combination With Cisplatin and Docetaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Enrollment Status: Completed
Publish Date: July 22, 2026
Intervention Type: Drug
Study Phase: Phase 2
Phase II Study of Induction Checkpoint Blockade for Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection
Phase II Study of Induction Checkpoint Blockade for Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection
Enrollment Status: Completed
Publish Date: April 06, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Docetaxel, Ipilimumab, Nivolumab, Pemetrexed
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Study Of Induction Chemotherapy With Cisplatin/Carboplatin, And Docetaxel With Or Without Erlotinib In Patients With Head And Neck Squamous Cell Carcinomas Amenable For Surgical Resection
Randomized, Placebo-Controlled, Phase 2 Study Of Induction Chemotherapy With Cisplatin/Carboplatin, And Docetaxel With Or Without Erlotinib In Patients With Head And Neck Squamous Cell Carcinomas Amenable For Surgical Resection
Enrollment Status: Completed
Publish Date: November 26, 2025
Intervention Type: Behavioral, Drug, Other
Study Drugs: Docetaxel, Erlotinib
Study Phase: Phase 2
Personalized, Randomized, Phase 2 Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias
Personalized, Randomized, Phase 2 Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias
Enrollment Status: Completed
Publish Date: October 23, 2025
Intervention Type: Other, Biological
Study Phase: Phase 2
Intensified Chemo-immuno-radiotherapy With Durvalumab (MEDI4736) for Stage III Non-Small Cell Lung Cancers (NSCLCs): a Brazilian Single Arm Phase II Study (PACIFIC BRAZIL)
Intensified Chemo-immuno-radiotherapy With Durvalumab (MEDI4736) for Stage III Non-Small Cell Lung Cancers (NSCLCs): a Brazilian Single Arm Phase II Study (PACIFIC BRAZIL)
Enrollment Status: Completed
Publish Date: February 11, 2025
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
Neoadjuvant Chemotherapy With Docetaxel, Cisplatin Followed by Maintenance Therapy With the EGFR Inhibitor Erlotinib (Tarceva) in Patients With Stage I, II and III Non-Small Cell Lung Cancer Following Definitive Surgical Resection
Neoadjuvant Chemotherapy With Docetaxel, Cisplatin Followed by Maintenance Therapy With the EGFR Inhibitor Erlotinib (Tarceva) in Patients With Stage I, II and III Non-Small Cell Lung Cancer Following Definitive Surgical Resection
Enrollment Status: Completed
Publish Date: July 05, 2024
Intervention Type: Drug, Other
Study Drugs: Cisplatin, Docetaxel, Erlotinib, Erlotinib Hydrochloride
Study Phase: Phase 1
Phase I Study of Induction Cisplatin, Docetaxel, and Nintedanib for Stage IB-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection
Phase I Study of Induction Cisplatin, Docetaxel, and Nintedanib for Stage IB-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection
Enrollment Status: Completed
Publish Date: May 08, 2024
Intervention Type: Drug, Other
Study Drugs: Cisplatin, Docetaxel, Nintedanib
Study Phase: Phase 1
A Phase II Evaluation of Avastin in Combination With Docetaxel and Carboplatin as Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer
A Phase II Evaluation of Avastin in Combination With Docetaxel and Carboplatin as Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: May 11, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of Erlotinib (Tarceva) in Combination With Bexarotene (Targretin) in Chemorefractory Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Phase II Study of Erlotinib (Tarceva) in Combination With Bexarotene (Targretin) in Chemorefractory Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: January 29, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

Frequently Asked Questions about William N. William

Is William N. William a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. William N. William is classified as an Experienced expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. William's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile